Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the progno...

Full description

Saved in:
Bibliographic Details
Published inBiomarker research Vol. 12; no. 1; p. 26
Main Authors Zhang, Nan, Yang, Xu, Piao, Mingjian, Xun, Ziyu, Wang, Yunchao, Ning, Cong, Zhang, Xinmu, Zhang, Longhao, Wang, Yanyu, Wang, Shanshan, Chao, Jiashuo, Lu, Zhenhui, Yang, Xiaobo, Wang, Hanping, Zhao, Haitao
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 14.02.2024
BioMed Central
BMC
Subjects
Antigens
Apoptosis
B cells
Biological markers
Biomarker
Biomarkers
Biopsy
C-reactive protein
Cells
Clinical trials
Copy number
Cytokines
Dendritic cells
Development and progression
Extracellular matrix
Forecasts and trends
Gene expression
Genes
Hepatocellular carcinoma
Hepatoma
Immune checkpoint inhibitors
Immunotherapy
Intestinal microflora
Kinases
L-Lactate dehydrogenase
Liver
Liver cancer
Liver diseases
Lymphocytes
Macrophages
Medical prognosis
Medical research
Medicine, Experimental
Metabolomics
Metastases
Metastasis
Monoclonal antibodies
p53 Protein
Patients
PD-1 protein
PD-L1 protein
PET imaging
Prognosis
Programmed death ligand 1
Programmed death-1
Prothrombin
Response rates
Review
Spatial distribution
Thrombin
Tumor proteins
Tumor-infiltrating lymphocytes
Tumors
Vascular endothelial growth factor
Wnt protein
β-Catenin
France
Finland
Hepatocellular carcinoma
Biomarker
Immune checkpoint inhibitors
Programmed death ligand 1
Programmed death-1
Online AccessGet full text

Cover

Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/β-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy.
AbstractList Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/β-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy.
Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/[beta]-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy.
Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/β-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy.
Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/β-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy.
Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/[beta]-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy. Keywords: Hepatocellular carcinoma, Programmed death-1, Programmed death ligand 1, Immune checkpoint inhibitors, Biomarker
ArticleNumber 26
Audience Academic
Author Ning, Cong
Lu, Zhenhui
Zhang, Longhao
Wang, Yanyu
Wang, Shanshan
Zhang, Nan
Yang, Xu
Wang, Hanping
Zhang, Xinmu
Xun, Ziyu
Chao, Jiashuo
Wang, Yunchao
Piao, Mingjian
Yang, Xiaobo
Zhao, Haitao
Author_xml – sequence: 1
  givenname: Nan
  surname: Zhang
  fullname: Zhang, Nan
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 2
  givenname: Xu
  surname: Yang
  fullname: Yang, Xu
  organization: Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Beijing, 100730, China
– sequence: 3
  givenname: Mingjian
  surname: Piao
  fullname: Piao, Mingjian
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 4
  givenname: Ziyu
  surname: Xun
  fullname: Xun, Ziyu
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 5
  givenname: Yunchao
  surname: Wang
  fullname: Wang, Yunchao
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 6
  givenname: Cong
  surname: Ning
  fullname: Ning, Cong
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 7
  givenname: Xinmu
  surname: Zhang
  fullname: Zhang, Xinmu
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 8
  givenname: Longhao
  surname: Zhang
  fullname: Zhang, Longhao
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 9
  givenname: Yanyu
  surname: Wang
  fullname: Wang, Yanyu
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 10
  givenname: Shanshan
  surname: Wang
  fullname: Wang, Shanshan
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 11
  givenname: Jiashuo
  surname: Chao
  fullname: Chao, Jiashuo
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China
– sequence: 12
  givenname: Zhenhui
  surname: Lu
  fullname: Lu, Zhenhui
  organization: Hepatobiliary and Pancreatic Surgery, Shenzhen Qianhai Shekou Free Trade Zone Hospital, No.36 Industrial 8 Road, Nanshan District, Shenzhen City, Guangdong province, China
– sequence: 13
  givenname: Xiaobo
  surname: Yang
  fullname: Yang, Xiaobo
  email: yangxiaobo67@pumch.cn
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China. yangxiaobo67@pumch.cn
– sequence: 14
  givenname: Hanping
  surname: Wang
  fullname: Wang, Hanping
  email: Wanghp@pumch.cn
  organization: Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Wanghp@pumch.cn
– sequence: 15
  givenname: Haitao
  surname: Zhao
  fullname: Zhao, Haitao
  email: zhaoht@pumch.cn
  organization: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Beijing, 100730, China. zhaoht@pumch.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38355603$$D View this record in MEDLINE/PubMed
BookMark eNptUttu1DAQjVARLaU_wAOKxAs8pPUljp0nVMptpZVAXJ6tiTPZdcnGi50Uul_PbLeULsKR7GjmnDOao_M4OxjCgFn2lLNTzk11lkomq7JgQhaMKamKzYPsSDDFCq01P7j3f5idpHTJ6BhTcl4_yg6lkUpVTB5lm9c-rCB-x5hyGNp8HcNiCGn0Lu_AjYHKocs_vSn4GV1znvth6RtPjaKBhG0-LjHC-prq-RpGj8OY8p9-XObQXsHgCLFEagSHfT_1EHMH0fmBhj7JHnbQJzy5fY-zb-_efr34UMw_vp9dnM8Lp2ozFnXFWcsa6TgqzqFloFuswAjXVDV54EQtSjC6KTUHrLHVWjZCGckbBEfE42y2020DXNp19LTvtQ3g7U0hxIWFSAv3aEHXTYcGFZau1I1oahKukEaj0aZSpPVqp7WemhW2jtaN0O-J7ncGv7SLcGU5I7oymhRe3CrE8GPCNNqVT1tzYMAwJUvbaMGF1Iagz_-BXoYpDuQVoVRlKilU_Re1ANrAD12gwW4ras-1EUoLI7dap_9B0dfiyjuKVuepvkd4uUcgzIi_xgVMKdnZl8_7WLHDuhhSitjdGcKZ3abV7tJqKa32Jq12Q6Rn9628o_zJpvwNyTzmWg
CitedBy_id crossref_primary_10_3748_wjg_v30_i19_2512
crossref_primary_10_2147_JHC_S469449
crossref_primary_10_1080_14712598_2024_2363234
crossref_primary_10_1016_j_meomic_2024_100039
Cites_doi 10.3390/cancers14030827
10.1007/s00270-021-03031-9
10.1158/1078-0432.CCR-20-1497
10.1016/j.jhep.2021.11.030
10.1200/JCO.19.01307
10.1158/1078-0432.CCR-18-2293
10.1056/NEJMoa1717002
10.1158/1078-0432.CCR-19-3840
10.1200/JCO.2020.38.15_suppl.4584
10.1007/s12072-022-10480-y
10.2967/jnumed.123.265712
10.3390/cancers13071607
10.1136/jitc-2020-001435
10.1016/j.jhep.2022.03.018
10.1016/j.ejca.2022.02.009
10.1093/annonc/mdx108
10.1016/j.jhep.2021.09.035
10.1002/hep.27665
10.1200/JCO.21.00163
10.1016/S1470-2045(21)00252-7
10.1016/S0168-8278(20)32229-7
10.1007/s00432-018-2805-3
10.1136/jitc-2020-000987
10.1056/NEJMra1713263
10.3390/cancers14040883
10.1159/000518048
10.1001/jamaoncol.2019.0046
10.1159/000501275
10.3390/cancers12071862
10.1002/cncr.32339
10.3389/fonc.2020.01043
10.1016/j.ccell.2019.08.007
10.1136/jitc-2021-003334
10.1158/1538-7445.AM2020-CT044
10.1016/S2468-1253(21)00109-6
10.1016/j.annonc.2020.04.078
10.1016/j.jhep.2021.06.028
10.1038/s41392-022-01235-0
10.1158/1078-0432.CCR-20-2571
10.1038/s41591-018-0085-8
10.1016/S1470-2045(18)30351-6
10.1001/jamaoncol.2023.4003
10.1200/JCO.2022.40.16_suppl.4119
10.1001/jamaoncol.2020.4564
10.1200/JCO.2020.38.15_suppl.3531
10.1016/S0140-6736(16)32453-9
10.1016/j.annonc.2022.08.031
10.1016/j.jhep.2018.03.019
10.1016/j.ejca.2020.04.025
10.1159/000505933
10.1159/000518619
10.1158/1078-0432.CCR-16-2128
10.1136/jitc-2022-004779
10.1007/s00262-019-02299-8
10.1111/liv.14210
10.1016/j.jhep.2016.10.029
10.1038/s41586-022-05400-x
10.1016/S0140-6736(18)30207-1
10.1186/s12885-021-08428-w
10.1136/jitc-2020-001033
10.1186/s40425-019-0650-9
10.1159/000488035
10.3389/fonc.2022.884372
10.1126/science.aaa4972
10.1200/JCO.2022.40.4_suppl.383
10.1158/2159-8290.CD-19-0074
10.2147/JHC.S401647
10.1158/1078-0432.CCR-20-3094
10.1016/j.cell.2017.09.028
10.1016/S1470-2045(22)00326-6
10.1038/s41571-018-0073-4
10.1186/s40364-021-00348-y
10.1186/s12967-020-02449-y
10.1093/annonc/mdz394.029
10.1016/j.jhep.2020.07.026
10.1038/s41568-019-0116-x
10.1016/S1470-2045(20)30011-5
10.3390/cancers12051221
10.1016/S1470-2045(21)00604-5
10.1200/JCO.2020.38.4_suppl.480
10.1056/EVIDoa2100070
10.1093/oncolo/oyac189
10.1002/hep4.1577
10.1016/S0140-6736(23)00961-3
10.1016/j.jhep.2023.01.011
10.1136/jitc-2020-001942
10.1056/NEJMoa0708857
10.1056/NEJMoa1915745
10.1038/s41590-018-0044-z
10.1016/S1470-2045(20)30156-X
10.1016/j.phrs.2022.106583
10.1016/S1470-2045(23)00411-4
10.1016/j.jhep.2014.06.008
10.1186/s40425-019-0766-y
10.1016/S0140-6736(17)31046-2
10.3390/cancers12071968
10.1245/s10434-018-6506-6
10.1016/S1470-2045(18)30937-9
10.1186/s13073-023-01218-y
10.2217/fon-2021-1261
10.1038/s41586-021-03362-0
10.1016/j.ebiom.2019.03.022
10.1016/j.annonc.2020.08.1107
10.1016/j.jhep.2020.08.010
10.1186/s40425-018-0314-1
10.1016/j.cell.2016.03.001
10.1016/j.immuni.2016.03.012
10.2147/JHC.S277453
10.1159/000529636
10.1002/cam4.3135
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024
DBID NPM
AAYXX
CITATION
ISR
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PIMPY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s40364-023-00535-z
DatabaseName PubMed
CrossRef
Gale In Context: Science
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
Biological Sciences
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest One Academic
MEDLINE - Academic
DatabaseTitleList


Publicly Available Content Database
MEDLINE - Academic
CrossRef
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2050-7771
EndPage 26
ExternalDocumentID oai_doaj_org_article_a79bfe8e5e4c47b2b9a876ec1ee87865
A782572838
10_1186_s40364_023_00535_z
38355603
Genre Journal Article
Review
GeographicLocations France
Finland
GeographicLocations_xml – name: Finland
– name: France
GrantInformation_xml – fundername: CAMS Innovation Fund for Medical Sciences（CIFMS)
  grantid: 2022-I2M-C&T-A-003
– fundername: CAMS Innovation Fund for Medical Sciences
  grantid: 2021-I2M-1-003
– fundername: National High Level Hospital Clinical Research Funding
  grantid: 2022-PUMCH-B-128
– fundername: CAMS Innovation Fund for Medical Sciences (CIFMS)
  grantid: 2021-I2M-1-061
– fundername: National Ten-thousand Talent Program
  grantid: Not applicable
GroupedDBID -A0
0R~
53G
5VS
8FE
8FH
AAFWJ
AAJSJ
ACGFS
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AFKRA
AFPKN
AHBYD
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
ASPBG
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
C24
C6C
CCPQU
DIK
EBLON
EBS
GROUPED_DOAJ
HCIFZ
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
LK8
M7P
M~E
NPM
OK1
PGMZT
PIMPY
PROAC
RBZ
ROL
RPM
RSV
SOJ
AAYXX
CITATION
ABVAZ
AFGXO
AFNRJ
ABUWG
AZQEC
DWQXO
GNUQQ
M48
PQEST
PQQKQ
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c598t-9610d0b3c1e511ad0a7de6a82cb69036c2924a87b471ae9ed773b25831beac0b3
IEDL.DBID RPM
ISSN 2050-7771
IngestDate Sun Sep 29 07:11:37 EDT 2024
Tue Sep 17 21:29:53 EDT 2024
Fri Aug 16 21:11:44 EDT 2024
Thu Oct 10 18:29:44 EDT 2024
Fri Feb 23 00:20:37 EST 2024
Tue Feb 20 11:59:12 EST 2024
Sat Sep 28 21:32:50 EDT 2024
Thu Sep 12 18:08:15 EDT 2024
Tue Oct 15 08:47:17 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hepatocellular carcinoma
Biomarker
Immune checkpoint inhibitors
Programmed death ligand 1
Programmed death-1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c598t-9610d0b3c1e511ad0a7de6a82cb69036c2924a87b471ae9ed773b25831beac0b3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10865587/
PMID 38355603
PQID 2956863259
PQPubID 2040162
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_a79bfe8e5e4c47b2b9a876ec1ee87865
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10865587
proquest_miscellaneous_2927212378
proquest_journals_2956863259
gale_infotracmisc_A782572838
gale_infotracacademiconefile_A782572838
gale_incontextgauss_ISR_A782572838
crossref_primary_10_1186_s40364_023_00535_z
pubmed_primary_38355603
PublicationCentury 2000
PublicationDate 2024-02-14
PublicationDateYYYYMMDD 2024-02-14
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-14
  day: 14
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Biomarker research
PublicationTitleAlternate Biomark Res
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References HS Kim (535_CR51) 2020; 38
535_CR8
AX Zhu (535_CR49) 2020; 80
T Aoki (535_CR67) 2021; 10
S Qin (535_CR97) 2021; 39
L Xu (535_CR115) 2022; 16
Y Chen (535_CR9) 2015; 61
M Kudo (535_CR103) 2022; 167
AL Cheng (535_CR107) 2022; 76
535_CR65
G Wang (535_CR71) 2022; 12
AG Duffy (535_CR23) 2017; 66
PS Sung (535_CR50) 2020; 10
D Balli (535_CR27) 2017; 23
535_CR68
D Agdashian (535_CR26) 2019; 68
H Ao (535_CR83) 2021; 9
M Kudo (535_CR96) 2018; 391
O Nigro (535_CR82) 2020; 134
KYY Ng (535_CR79) 2022; 11
A Villanueva (535_CR2) 2019; 380
N Riaz (535_CR21) 2017; 171
535_CR75
European Association for the Study of the Liver (535_CR1) 2018; 69
X Cui (535_CR33) 2023; 187
X Wang (535_CR72) 2023; 10
535_CR78
H Salmon (535_CR30) 2016; 44
AB El-Khoueiry (535_CR5) 2017; 389
LG Feun (535_CR63) 2019; 125
Y Liu (535_CR37) 2023; 78
G Ho (535_CR73) 2022; 63
J Long (535_CR45) 2019; 42
R Xue (535_CR36) 2022; 612
JM Llovet (535_CR95) 2008; 359
Z Ren (535_CR110) 2021; 22
M Ringelhan (535_CR4) 2018; 19
L Zitvogel (535_CR90) 2016; 165
535_CR48
535_CR47
S Narayanan (535_CR28) 2018; 25
B Sangro (535_CR22) 2020; 73
L Li (535_CR42) 2020; 19
JJ Havel (535_CR13) 2019; 19
S Qin (535_CR105) 2022; 40
535_CR53
HD Zhu (535_CR39) 2023; 8
A Qayyum (535_CR69) 2019; 7
X Sun (535_CR76) 2021; 21
Y Zheng (535_CR92) 2019; 7
535_CR59
535_CR58
HT Quach (535_CR80) 2019; 5
RS Finn (535_CR113) 2022; 33
535_CR57
535_CR56
S Zhang (535_CR38) 2023; 15
GK Abou-Alfa (535_CR19) 2022; 1
B Sangro (535_CR7) 2020; 31
J Zhou (535_CR3) 2018; 7
RS Finn (535_CR12) 2020; 382
S Dharmapuri (535_CR77) 2020; 9
LC Lu (535_CR54) 2019; 8
P Winograd (535_CR84) 2020; 4
535_CR29
J Xu (535_CR111) 2021; 27
B-Y Ryoo (535_CR108) 2023; 41
J Zhu (535_CR20) 2018; 6
535_CR25
L Bassaganyas (535_CR44) 2020; 26
535_CR104
535_CR24
535_CR102
S Chen (535_CR64) 2020; 7
KC Barry (535_CR31) 2018; 24
A Ueno (535_CR66) 2014; 61
S Qin (535_CR112) 2023; 402
F Jia (535_CR109) 2020; 31
MS Lee (535_CR15) 2020; 21
M Huang (535_CR52) 2020; 26
JM Llovet (535_CR43) 2018; 15
AX Zhu (535_CR6) 2018; 19
WS Garrett (535_CR89) 2015; 348
B Scheiner (535_CR61) 2022; 76
AX Zhu (535_CR32) 2020; 80
RK Kelley (535_CR114) 2022; 23
535_CR88
J Li (535_CR85) 2020; 18
A Qayyum (535_CR70) 2020; 38
S Qin (535_CR100) 2021; 6
JM Llovet (535_CR40) 2022; 45
AX Zhu (535_CR101) 2019; 20
JW Franses (535_CR87) 2022; 27
X Gao (535_CR116) 2023; 24
T Yau (535_CR14) 2022; 23
Y Yang (535_CR62) 2022; 77
535_CR106
L Ma (535_CR34) 2019; 36
M Wu (535_CR74) 2023; 64
M Ruiz de Galarreta (535_CR46) 2019; 9
J Bruix (535_CR98) 2017; 389
N Ben Khaled (535_CR41) 2022; 18
D Pfister (535_CR60) 2021; 592
C-H Hsu (535_CR86) 2020; 38
S Qin (535_CR16) 2020; 21
HY Kuo (535_CR55) 2020; 43
GK Abou-Alfa (535_CR99) 2018; 379
535_CR11
535_CR10
L Ma (535_CR35) 2021; 75
535_CR94
535_CR93
535_CR18
535_CR17
B Ricciuti (535_CR81) 2019; 145
N Chaput (535_CR91) 2017; 28
References_xml – ident: 535_CR68
  doi: 10.3390/cancers14030827
– volume: 45
  start-page: 405
  issue: 4
  year: 2022
  ident: 535_CR40
  publication-title: Cardiovasc Intervent Radiol
  doi: 10.1007/s00270-021-03031-9
  contributor:
    fullname: JM Llovet
– volume: 26
  start-page: 6350
  issue: 23
  year: 2020
  ident: 535_CR44
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1497
  contributor:
    fullname: L Bassaganyas
– volume: 76
  start-page: 862
  issue: 4
  year: 2022
  ident: 535_CR107
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.11.030
  contributor:
    fullname: AL Cheng
– volume: 41
  start-page: 4010
  issue: 16suppl
  year: 2023
  ident: 535_CR108
  publication-title: J Clin Oncol
  contributor:
    fullname: B-Y Ryoo
– ident: 535_CR8
  doi: 10.1200/JCO.19.01307
– ident: 535_CR47
  doi: 10.1158/1078-0432.CCR-18-2293
– volume: 379
  start-page: 54
  issue: 1
  year: 2018
  ident: 535_CR99
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1717002
  contributor:
    fullname: GK Abou-Alfa
– volume: 26
  start-page: 4947
  issue: 18
  year: 2020
  ident: 535_CR52
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-3840
  contributor:
    fullname: M Huang
– volume: 38
  start-page: 4584
  issue: 15suppl
  year: 2020
  ident: 535_CR51
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.4584
  contributor:
    fullname: HS Kim
– ident: 535_CR53
  doi: 10.1007/s12072-022-10480-y
– volume: 64
  start-page: 1532
  issue: 10
  year: 2023
  ident: 535_CR74
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.123.265712
  contributor:
    fullname: M Wu
– volume: 16
  start-page: 24
  issue: S1
  year: 2022
  ident: 535_CR115
  publication-title: Immuno-Oncology and Technology
  contributor:
    fullname: L Xu
– ident: 535_CR59
  doi: 10.3390/cancers13071607
– ident: 535_CR11
  doi: 10.1136/jitc-2020-001435
– volume: 77
  start-page: 574
  issue: 2
  year: 2022
  ident: 535_CR62
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2022.03.018
  contributor:
    fullname: Y Yang
– volume: 167
  start-page: 1
  year: 2022
  ident: 535_CR103
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2022.02.009
  contributor:
    fullname: M Kudo
– volume: 28
  start-page: 1368
  issue: 6
  year: 2017
  ident: 535_CR91
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx108
  contributor:
    fullname: N Chaput
– volume: 76
  start-page: 353
  issue: 2
  year: 2022
  ident: 535_CR61
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.09.035
  contributor:
    fullname: B Scheiner
– volume: 61
  start-page: 1591
  issue: 5
  year: 2015
  ident: 535_CR9
  publication-title: Hepatology
  doi: 10.1002/hep.27665
  contributor:
    fullname: Y Chen
– volume: 39
  start-page: 3002
  issue: 27
  year: 2021
  ident: 535_CR97
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.00163
  contributor:
    fullname: S Qin
– volume: 22
  start-page: 977
  issue: 7
  year: 2021
  ident: 535_CR110
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00252-7
  contributor:
    fullname: Z Ren
– ident: 535_CR48
  doi: 10.1016/S0168-8278(20)32229-7
– volume: 145
  start-page: 479
  issue: 2
  year: 2019
  ident: 535_CR81
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-018-2805-3
  contributor:
    fullname: B Ricciuti
– ident: 535_CR24
  doi: 10.1136/jitc-2020-000987
– volume: 380
  start-page: 1450
  issue: 15
  year: 2019
  ident: 535_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1713263
  contributor:
    fullname: A Villanueva
– ident: 535_CR65
  doi: 10.3390/cancers14040883
– volume: 10
  start-page: 615
  issue: 6
  year: 2021
  ident: 535_CR67
  publication-title: Liver Cancer
  doi: 10.1159/000518048
  contributor:
    fullname: T Aoki
– volume: 5
  start-page: 906
  issue: 6
  year: 2019
  ident: 535_CR80
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.0046
  contributor:
    fullname: HT Quach
– volume: 8
  start-page: 480
  issue: 6
  year: 2019
  ident: 535_CR54
  publication-title: Liver Cancer
  doi: 10.1159/000501275
  contributor:
    fullname: LC Lu
– ident: 535_CR57
  doi: 10.3390/cancers12071862
– volume: 125
  start-page: 3603
  issue: 20
  year: 2019
  ident: 535_CR63
  publication-title: Cancer
  doi: 10.1002/cncr.32339
  contributor:
    fullname: LG Feun
– volume: 10
  start-page: 1043
  year: 2020
  ident: 535_CR50
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.01043
  contributor:
    fullname: PS Sung
– volume: 36
  start-page: 418
  issue: 4
  year: 2019
  ident: 535_CR34
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.08.007
  contributor:
    fullname: L Ma
– ident: 535_CR93
  doi: 10.1136/jitc-2021-003334
– volume: 80
  start-page: CT044
  issue: 16Supplement
  year: 2020
  ident: 535_CR32
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2020-CT044
  contributor:
    fullname: AX Zhu
– volume: 6
  start-page: 559
  issue: 7
  year: 2021
  ident: 535_CR100
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(21)00109-6
  contributor:
    fullname: S Qin
– volume: 31
  start-page: 241
  year: 2020
  ident: 535_CR7
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.04.078
  contributor:
    fullname: B Sangro
– volume: 75
  start-page: 1397
  issue: 6
  year: 2021
  ident: 535_CR35
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.06.028
  contributor:
    fullname: L Ma
– volume: 8
  start-page: 58
  issue: 1
  year: 2023
  ident: 535_CR39
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-022-01235-0
  contributor:
    fullname: HD Zhu
– volume: 27
  start-page: 1003
  issue: 4
  year: 2021
  ident: 535_CR111
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-2571
  contributor:
    fullname: J Xu
– volume: 24
  start-page: 1178
  issue: 8
  year: 2018
  ident: 535_CR31
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0085-8
  contributor:
    fullname: KC Barry
– volume: 19
  start-page: 940
  issue: 7
  year: 2018
  ident: 535_CR6
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30351-6
  contributor:
    fullname: AX Zhu
– ident: 535_CR106
  doi: 10.1001/jamaoncol.2023.4003
– ident: 535_CR25
  doi: 10.1200/JCO.2022.40.16_suppl.4119
– volume: 80
  start-page: CT044
  issue: 16 Supplement
  year: 2020
  ident: 535_CR49
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2020-CT044
  contributor:
    fullname: AX Zhu
– ident: 535_CR17
  doi: 10.1001/jamaoncol.2020.4564
– volume: 38
  start-page: 3531
  issue: 15suppl
  year: 2020
  ident: 535_CR86
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.3531
  contributor:
    fullname: C-H Hsu
– volume: 389
  start-page: 56
  issue: 10064
  year: 2017
  ident: 535_CR98
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32453-9
  contributor:
    fullname: J Bruix
– volume: 33
  start-page: 808
  year: 2022
  ident: 535_CR113
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2022.08.031
  contributor:
    fullname: RS Finn
– volume: 69
  start-page: 182
  issue: 1
  year: 2018
  ident: 535_CR1
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.03.019
  contributor:
    fullname: European Association for the Study of the Liver
– volume: 134
  start-page: 19
  year: 2020
  ident: 535_CR82
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2020.04.025
  contributor:
    fullname: O Nigro
– volume: 43
  start-page: 211
  issue: 5
  year: 2020
  ident: 535_CR55
  publication-title: Oncol Res Treat
  doi: 10.1159/000505933
  contributor:
    fullname: HY Kuo
– volume: 11
  start-page: 9
  issue: 1
  year: 2022
  ident: 535_CR79
  publication-title: Liver Cancer
  doi: 10.1159/000518619
  contributor:
    fullname: KYY Ng
– volume: 23
  start-page: 3129
  issue: 12
  year: 2017
  ident: 535_CR27
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-2128
  contributor:
    fullname: D Balli
– ident: 535_CR94
  doi: 10.1136/jitc-2022-004779
– volume: 68
  start-page: 599
  issue: 4
  year: 2019
  ident: 535_CR26
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-019-02299-8
  contributor:
    fullname: D Agdashian
– ident: 535_CR75
  doi: 10.1111/liv.14210
– volume: 66
  start-page: 545
  issue: 3
  year: 2017
  ident: 535_CR23
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.10.029
  contributor:
    fullname: AG Duffy
– volume: 612
  start-page: 141
  issue: 7938
  year: 2022
  ident: 535_CR36
  publication-title: Nature
  doi: 10.1038/s41586-022-05400-x
  contributor:
    fullname: R Xue
– volume: 391
  start-page: 1163
  issue: 10126
  year: 2018
  ident: 535_CR96
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)30207-1
  contributor:
    fullname: M Kudo
– volume: 21
  start-page: 775
  issue: 1
  year: 2021
  ident: 535_CR76
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08428-w
  contributor:
    fullname: X Sun
– ident: 535_CR58
  doi: 10.1136/jitc-2020-001033
– volume: 7
  start-page: 193
  issue: 1
  year: 2019
  ident: 535_CR92
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0650-9
  contributor:
    fullname: Y Zheng
– volume: 7
  start-page: 235
  issue: 3
  year: 2018
  ident: 535_CR3
  publication-title: Liver Cancer
  doi: 10.1159/000488035
  contributor:
    fullname: J Zhou
– volume: 12
  start-page: 884372
  year: 2022
  ident: 535_CR71
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.884372
  contributor:
    fullname: G Wang
– volume: 348
  start-page: 80
  issue: 6230
  year: 2015
  ident: 535_CR89
  publication-title: Science
  doi: 10.1126/science.aaa4972
  contributor:
    fullname: WS Garrett
– volume: 40
  start-page: 383
  issue: 4suppl
  year: 2022
  ident: 535_CR105
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2022.40.4_suppl.383
  contributor:
    fullname: S Qin
– volume: 9
  start-page: 1124
  issue: 8
  year: 2019
  ident: 535_CR46
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-19-0074
  contributor:
    fullname: M Ruiz de Galarreta
– volume: 10
  start-page: 587
  year: 2023
  ident: 535_CR72
  publication-title: J Hepatocell Carcinoma
  doi: 10.2147/JHC.S401647
  contributor:
    fullname: X Wang
– ident: 535_CR18
  doi: 10.1158/1078-0432.CCR-20-3094
– volume: 171
  start-page: 934
  issue: 4
  year: 2017
  ident: 535_CR21
  publication-title: Cell
  doi: 10.1016/j.cell.2017.09.028
  contributor:
    fullname: N Riaz
– volume: 23
  start-page: 995
  issue: 8
  year: 2022
  ident: 535_CR114
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(22)00326-6
  contributor:
    fullname: RK Kelley
– volume: 15
  start-page: 599
  issue: 10
  year: 2018
  ident: 535_CR43
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-018-0073-4
  contributor:
    fullname: JM Llovet
– volume: 9
  start-page: 91
  issue: 1
  year: 2021
  ident: 535_CR83
  publication-title: Biomark Res
  doi: 10.1186/s40364-021-00348-y
  contributor:
    fullname: H Ao
– volume: 18
  start-page: 293
  issue: 1
  year: 2020
  ident: 535_CR85
  publication-title: J Transl Med
  doi: 10.1186/s12967-020-02449-y
  contributor:
    fullname: J Li
– ident: 535_CR102
  doi: 10.1093/annonc/mdz394.029
– volume: 73
  start-page: 1460
  issue: 6
  year: 2020
  ident: 535_CR22
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.07.026
  contributor:
    fullname: B Sangro
– volume: 19
  start-page: 2739
  issue: 4
  year: 2020
  ident: 535_CR42
  publication-title: Oncol Lett
  contributor:
    fullname: L Li
– volume: 19
  start-page: 133
  issue: 3
  year: 2019
  ident: 535_CR13
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0116-x
  contributor:
    fullname: JJ Havel
– volume: 21
  start-page: 571
  issue: 4
  year: 2020
  ident: 535_CR16
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30011-5
  contributor:
    fullname: S Qin
– ident: 535_CR29
  doi: 10.3390/cancers12051221
– volume: 23
  start-page: 77
  issue: 1
  year: 2022
  ident: 535_CR14
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00604-5
  contributor:
    fullname: T Yau
– volume: 38
  start-page: 480
  issue: 4suppl
  year: 2020
  ident: 535_CR70
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.4_suppl.480
  contributor:
    fullname: A Qayyum
– volume: 1
  start-page: EVIDoa2100070
  issue: 8
  year: 2022
  ident: 535_CR19
  publication-title: NEJM Evid
  doi: 10.1056/EVIDoa2100070
  contributor:
    fullname: GK Abou-Alfa
– volume: 27
  start-page: e908
  issue: 11
  year: 2022
  ident: 535_CR87
  publication-title: Oncologist
  doi: 10.1093/oncolo/oyac189
  contributor:
    fullname: JW Franses
– volume: 4
  start-page: 1527
  issue: 10
  year: 2020
  ident: 535_CR84
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.1577
  contributor:
    fullname: P Winograd
– volume: 63
  start-page: 2376
  issue: supplement 2
  year: 2022
  ident: 535_CR73
  publication-title: J Nucl Med
  contributor:
    fullname: G Ho
– volume: 402
  start-page: 1133
  issue: 10408
  year: 2023
  ident: 535_CR112
  publication-title: Lancet
  doi: 10.1016/S0140-6736(23)00961-3
  contributor:
    fullname: S Qin
– ident: 535_CR10
– volume: 78
  start-page: 770
  issue: 4
  year: 2023
  ident: 535_CR37
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2023.01.011
  contributor:
    fullname: Y Liu
– ident: 535_CR88
  doi: 10.1136/jitc-2020-001942
– volume: 359
  start-page: 378
  issue: 4
  year: 2008
  ident: 535_CR95
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0708857
  contributor:
    fullname: JM Llovet
– volume: 382
  start-page: 1894
  issue: 20
  year: 2020
  ident: 535_CR12
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1915745
  contributor:
    fullname: RS Finn
– volume: 19
  start-page: 222
  issue: 3
  year: 2018
  ident: 535_CR4
  publication-title: Nat Immunol
  doi: 10.1038/s41590-018-0044-z
  contributor:
    fullname: M Ringelhan
– volume: 21
  start-page: 808
  issue: 6
  year: 2020
  ident: 535_CR15
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30156-X
  contributor:
    fullname: MS Lee
– volume: 187
  start-page: 106583
  year: 2023
  ident: 535_CR33
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2022.106583
  contributor:
    fullname: X Cui
– volume: 24
  start-page: 1134
  issue: 10
  year: 2023
  ident: 535_CR116
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(23)00411-4
  contributor:
    fullname: X Gao
– volume: 61
  start-page: 1080
  issue: 5
  year: 2014
  ident: 535_CR66
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2014.06.008
  contributor:
    fullname: A Ueno
– volume: 7
  start-page: 329
  issue: 1
  year: 2019
  ident: 535_CR69
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0766-y
  contributor:
    fullname: A Qayyum
– volume: 389
  start-page: 2492
  issue: 10088
  year: 2017
  ident: 535_CR5
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)31046-2
  contributor:
    fullname: AB El-Khoueiry
– ident: 535_CR56
  doi: 10.3390/cancers12071968
– volume: 25
  start-page: 2323
  issue: 8
  year: 2018
  ident: 535_CR28
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-018-6506-6
  contributor:
    fullname: S Narayanan
– volume: 20
  start-page: 282
  issue: 2
  year: 2019
  ident: 535_CR101
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30937-9
  contributor:
    fullname: AX Zhu
– volume: 15
  start-page: 72
  issue: 1
  year: 2023
  ident: 535_CR38
  publication-title: Genome Med
  doi: 10.1186/s13073-023-01218-y
  contributor:
    fullname: S Zhang
– volume: 18
  start-page: 1423
  issue: 12
  year: 2022
  ident: 535_CR41
  publication-title: Future Oncol
  doi: 10.2217/fon-2021-1261
  contributor:
    fullname: N Ben Khaled
– volume: 592
  start-page: 450
  issue: 7854
  year: 2021
  ident: 535_CR60
  publication-title: Nature
  doi: 10.1038/s41586-021-03362-0
  contributor:
    fullname: D Pfister
– volume: 42
  start-page: 363
  year: 2019
  ident: 535_CR45
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.03.022
  contributor:
    fullname: J Long
– volume: 31
  start-page: 692
  year: 2020
  ident: 535_CR109
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.08.1107
  contributor:
    fullname: F Jia
– ident: 535_CR78
  doi: 10.1016/j.jhep.2020.08.010
– volume: 6
  start-page: 4
  issue: 1
  year: 2018
  ident: 535_CR20
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0314-1
  contributor:
    fullname: J Zhu
– volume: 165
  start-page: 276
  issue: 2
  year: 2016
  ident: 535_CR90
  publication-title: Cell
  doi: 10.1016/j.cell.2016.03.001
  contributor:
    fullname: L Zitvogel
– volume: 44
  start-page: 924
  issue: 4
  year: 2016
  ident: 535_CR30
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.03.012
  contributor:
    fullname: H Salmon
– volume: 7
  start-page: 289
  year: 2020
  ident: 535_CR64
  publication-title: J Hepatocell Carcinoma
  doi: 10.2147/JHC.S277453
  contributor:
    fullname: S Chen
– ident: 535_CR104
  doi: 10.1159/000529636
– volume: 9
  start-page: 4962
  issue: 14
  year: 2020
  ident: 535_CR77
  publication-title: Cancer Med
  doi: 10.1002/cam4.3135
  contributor:
    fullname: S Dharmapuri
SSID ssj0000884119
Score 2.3284683
SecondaryResourceType review_article
Snippet Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients...
Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some...
Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 26
SubjectTerms Antigens
Apoptosis
B cells
Biological markers
Biomarker
Biomarkers
Biopsy
C-reactive protein
Cells
Clinical trials
Copy number
Cytokines
Dendritic cells
Development and progression
Extracellular matrix
Forecasts and trends
Gene expression
Genes
Hepatocellular carcinoma
Hepatoma
Immune checkpoint inhibitors
Immunotherapy
Intestinal microflora
Kinases
L-Lactate dehydrogenase
Liver
Liver cancer
Liver diseases
Lymphocytes
Macrophages
Medical prognosis
Medical research
Medicine, Experimental
Metabolomics
Metastases
Metastasis
Monoclonal antibodies
p53 Protein
Patients
PD-1 protein
PD-L1 protein
PET imaging
Prognosis
Programmed death ligand 1
Programmed death-1
Prothrombin
Response rates
Review
Spatial distribution
Thrombin
Tumor proteins
Tumor-infiltrating lymphocytes
Tumors
Vascular endothelial growth factor
Wnt protein
β-Catenin
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQSkhcEMszsCCDkDggq7Xj2M5xeawWBAgBK-3Nsh1n2wMOatrD9tfvTJxWjThw4RJV8SRpZsaemXjmG0JeR1WrIIVkrcBtRiFa5jxEKS445bVpQtRY7_z1mzq_kJ8vq8uDVl-YE5bhgTPjZk7Xvo0mVlEGqb3wtYMJHAOP0WijMnoprw6CqWENNkZyXu-qZIya9RJ33BiYKDZgmrDtxBINgP1_L8sHdmmaM3lghM7ukbuj90hP878-Jrdiuk9u536S1w_IFn79xnybVU9daigmX6UOkZjp2FeHdi39_oHxGRy-cLpMi6WHOb1iaM0amquxruE8HQFXe4pfaukuVYAuwHytO_zcj_mrNGArogQPfUguzj7-en_OxuYKLFS1WbMa_KZm7ktgJPhcrpk73UTljAgeAuZSBQGRGbDag_VysY6N1qUXlSm5h7UaLnxEjlKX4hNClZcqNBIrTbiMApYtXxuum3npcddPFOTtjtH2T8bQsEPsYZTNYrEgFjuIxW4L8g5lsadE_OvhBGiFHbXC_ksrCvIKJWkR4SJhCs2V2_S9_fTzhz0Fn6jS4FWZgrwZidoOZBrcWJEAb4WgWBPKkwklTMEwHd4pjB2XgN4KLMRUJYSXBXm5H8YrMa0txW6DNEKj76DhFo-zfu3fuwTfGNzRsiBmonkTxkxH0nIxAIRj96yqMvrp_2DlM3JHgCOHmepcnpCj9WoTn4MjtvYvhjl3A5hBMQM
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLdgExIXxPcCAxmExAFZrR3Hdk5og00DwTQNJu1m2Y6z9kAymvaw_vW8l7hlERKXqopf2jjPfu_n90nIu6hKFaSQrBboZhSiZs7DKcUFp7w2VYga852_n6qTC_n1srhMBrcuhVVuZGIvqKs2oI18IjCvTeWA1j9e_2bYNQq9q6mFxl2yK7hEN-3u4dHp2fnWygJ7SHJebrJljJp0Ej1vDFQV62ubsPVII_WF-_8Vz7f00zh28pYyOn5IHiQUSQ8Gtj8id2LzmNwb-krePCFr-PYL424WHXVNRTEIq2mxIjNN_XVoW9Ozz4xP4OMbp_NmNvewtxcMtVpFh6ysG7hOU-HVjqLFlm5CBugM1NiyRbM_xrHSgC2JGvjTp-Ti-OjnpxOWmiywUJRmyUrAT9XU54FHwF6umjpdReWMCB4OzrkKAk5ozmgPWszFMlZa514UJuceZDbc-IzsNG0T9whVXqpQScw44TIKEF--NFxX09yj909k5MPmRdvroZaG7c8gRtmBLRbYYnu22HVGDpEXW0qsg91faBdXNm0r63Tp62hiEWWQ2gtfwqOqCJOJRhtVZOQtctJipYsGQ2mu3Krr7Jcf5_YAsFGhAV2ZjLxPRHULPA0uZSbArLA41ohyf0QJWzGMhzcLxiZR0Nm_Czcjb7bDeCeGtzWxXSGN0IghNPzE82F9beedA0YGWJpnxIxW3ujFjEea-awvFI5dtIrC6Bf_f66X5L4AqIax6Fzuk53lYhVfAdRa-tdpP_0BxMgo6Q
  priority: 102
  providerName: ProQuest
Title Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/38355603
https://www.proquest.com/docview/2956863259
https://search.proquest.com/docview/2927212378
https://pubmed.ncbi.nlm.nih.gov/PMC10865587
https://doaj.org/article/a79bfe8e5e4c47b2b9a876ec1ee87865
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtx2AvY9_z1hVtDPYw3MSyLMmPadfShbWEdoW-CUlWmsBilzh5aP763cl2iNnbXpJgnRzLp9PdSb-7I-SrF7lwnPF4yvCYkbFpbCx4KcYZYaUqnJcY73x5JS5u-fguu9sjoouFCaB9Z-fH5Z_FcTmfBWzlw8INOpzYYHJ5itWBskzJwT7Zl2m646OH9VcpniR5FyGjxKDmeNoWg3qKQz6TeNPTQiFZ_79L8o5O6uMldxTQ-QvyvLUc6ah5wpdkz5evyNOmluTja7KBXwvE2ixrasqCIvCqrDALM21r6tBqSic_4mQAH78SOi9ncwvyvIxRkxW0icR6hOu0TbZaU9ylpR1MgM5Ada0q3OpH7Cp1WIaohD99Q27Pz36fXsRtYYXYZblaxTnYTMXQpi7xYG-ZYmhk4YVRzFlwllPhGHhlRkkLmsv43BdSppZlKk0srNPQ8S05KKvSvydUWC5cwTHKJOGewZJlc5XIYphaPPFjEfnevWj90OTP0MHvUEI3bNHAFh3YojcROUFebCkx93W4UC3vdTsDtJG5nXrlM88dl5bZHB5VeBiMVxImRkS-ICc1ZrcoET5zb9Z1rX_eXOsR2EOZBItKReRbSzStgKfOtNEIMCpMiNWjPOxRgvi5fnM3YXQr_rVmGIQpUnAtI_J524w9EdJW-mqNNEyi3SDhFu-a-bUddwp2MZiiaURUb-b1Xky_BWQlJAfvZOPD_3f9SJ4xMN0Qm57wQ3KwWq79JzC9VvaIPBmNxjdj-D45u5pcH4UtjKMgf38BuYYzPw
link.rule.ids 230,315,733,786,790,870,891,2115,21416,27955,27956,33777,33778,43838,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgE4IXxDeBAQYh8YCsNo5jO09og00ddNU0Nmlvlu24ax9IRtM-rH89d4lbFiHxUlXxpY1z57ufz_dByMcgC-kFF2zK8ZiR8ymzDnYp1lvplC59UJjvfDKRowvx_TK_jA63JoZVbnRiq6jL2qOPfMAxr01mgNa_XP9m2DUKT1djC427ZBdLbuodsntwODk923pZYA2JNC022TJaDhqBJ28MTBVra5uwdc8itYX7_1XPt-xTP3byljE6ekQeRhRJ9zu2PyZ3QvWE3Ov6St48JWv49gvjbhYNtVVJMQirqrEiM439dWg9paffWDqAj3FK59Vs7mBtLxhatZJ2WVk3cJ3GwqsNRY8t3YQM0BmYsWWNbn-MY6UeWxJV8KfPyMXR4fnXEYtNFpjPC71kBeCncugynwbAXrYcWlUGaTX3DjbOmfQcdmhWKwdWzIYilEpljuc6Sx3obLjxOdmp6iq8JFQ6IX0pMOMkFYGD-nKFTlU5zBye_vGEfN68aHPd1dIw7R5ES9OxxQBbTMsWs07IAfJiS4l1sNsL9eLKxGVlrCrcNOiQB-GFctwV8KgywGSCVlrmCfmAnDRY6aLCUJoru2oac_zzzOwDNsoVoCudkE-RaFoDT72NmQkwKyyO1aPc61HCUvT94Y3AmKgKGvNXcBPyfjuMd2J4WxXqFdJwhRhCwU-86ORrO2-Q6xxgaZYQ3ZO83ovpj1TzWVsoHLto5blWr_7_XO_I_dH5ydiMjyc_XpMHHGAbxqWnYo_sLBer8AZg19K9jWvrD_f8K98
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgCMQL3x-FAQYh8YDSNE5iO49jo9pgmyZg0qQ9WLbjrBXUqZr2Yf3ructH1cDbXqooPje93Nl3V__ujpCPjmfcJiwJCobHjIwVgTYQpWiruREyt05gvvPJKT88T75dpBctqrJqYZXemunQ_5kN_XRSYyvnMxt2OLHw7GQfuwOlqRThPC_C2-QOLFomtiL1eheWMomirMuTkTysEjxzC8BIBXVVk2Dds0V1yf7_N-Yty9RHTW6ZofFDctkx0KBPfg9XSzO0639qO96Mw0fkQeud0r2G5jG55fwTcrfpV3n9lKzhaoZ4nkVFtc8pgrt8iZWeadu3h5YFPTsIohA-jiM69ZOpgT1jEaC1zGmT7XUN92lb0LWi-E8w7aAIdALmcVnicQLiY6nFVkceHvqMnI-__to_DNrmDYFNM7kMMvDL8pGJbeTAp9P5SIvccS2ZNRCQx9wyiPy0FAaso3aZy4WIDUtlHBmwBTDxOdnxpXcvCeUm4TZPMJMlShyDbdFkMhL5KDZ4qsgG5HMnRjVvanSoOraRXDVCVyB0VQtdrQfkC0p6Q4n1tesb5eJKtTJQWmSmcNKlLrGJMMxk8FO5A2acFCCaAfmAeqKwgoZHiM6VXlWVOvr5Q-2Bz5UK8NrkgHxqiYoSNMbqNuMBuMKiWz3K3R4lLHHbH-7UUbVbTKUYJnryGMLXAXm_GcaZCJvzrlwhDRPomwj4iheN9m74jsH3Bnc3HhDZ0-vei-mPgLbWBcg77Xx186nvyL2zg7E6Pjr9_prcZ-ApIhQ-SnbJznKxcm_A01uat_WS_gvlklPT
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biomarkers+and+prognostic+factors+of+PD-1%2FPD-L1+inhibitor-based+therapy+in+patients+with+advanced+hepatocellular+carcinoma&rft.jtitle=Biomarker+research&rft.au=Zhang%2C+Nan&rft.au=Yang%2C+Xu&rft.au=Piao%2C+Mingjian&rft.au=Xun%2C+Ziyu&rft.date=2024-02-14&rft.pub=BioMed+Central+Ltd&rft.issn=2050-7771&rft.eissn=2050-7771&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1186%2Fs40364-023-00535-z&rft.externalDocID=A782572838
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-7771&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-7771&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-7771&client=summon